Comparative Pharmacology
Head-to-head clinical analysis: LEDERCILLIN VK versus UNIPEN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEDERCILLIN VK versus UNIPEN IN PLASTIC CONTAINER.
LEDERCILLIN VK vs UNIPEN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is bactericidal against susceptible organisms during the active growth phase.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and peptidoglycan cross-linking.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
250-500 mg intravenously or intramuscularly every 4-6 hours. Maximum dose 12 g per day.
None Documented
None Documented
Terminal elimination half-life is 0.5 hours (range 0.4–0.6 hours) in adults with normal renal function. In severe renal impairment (CrCl <10 mL/min), half-life extends to ~4 hours.
0.5-1 hour (normal renal function); prolonged to 2-5 hours in renal impairment
Renal elimination predominantly via tubular secretion of unchanged drug (>90% of absorbed dose). Approximately 20-40% of an oral dose is recovered in urine as unchanged penicillin V. Biliary excretion accounts for <1% of elimination; fecal elimination is negligible.
Renal: 60-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: minor, <10%
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic